A recent study has suggested that increased Rac1 activity may be one consequence of disruptions of the PTEN tumor suppressor pathway in melanoma, raising the possibility that PTEN-deficient melanomas may represent another potential context for beneficial co-targeting of BRAF/MEK and FAK [47]. The gene discussed is RAC1; the disease is neoplasm.